| J&J says vaccine 66% effective against COVID-19 in large study A vaccine developed by J&J prevented moderate or severe COVID-19 in a large trial of about 45,000 volunteers, the company announced Friday. The vaccine's overall efficacy, at 66%, was somewhat lower than expected, falling short of the high bar set by shots from Pfizer and Moderna. Protection appeared weaker against new virus variants in Latin American and South Africa. J&J plans to ask the Food and Drug Administration for emergency clearance of the shot in early February. |
No comments:
Post a Comment